Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma.

Jeon MJ, Kim WG, Park WR, Han JM, Kim TY, Song DE, Chung KW, Ryu JS, Hong SJ, Shong YK, Kim WB.

Eur J Endocrinol. 2013 Nov 22;170(1):23-30. doi: 10.1530/EJE-13-0524. Print 2014 Jan.

2.

The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification.

Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, Larson SM, Tuttle RM, Shaha A, Shah JP.

Thyroid. 2013 Jun;23(6):683-94. doi: 10.1089/thy.2012.0307.

PMID:
23742290
3.

Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer.

Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, Kukulska A, Prokurat A, Wygoda Z, Jarzab B.

J Nucl Med. 2007 Jun;48(6):879-88.

5.

Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.

Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, Song DE, Hong SJ, Shong YK, Kim WB.

Thyroid. 2014 May;24(5):820-5. doi: 10.1089/thy.2013.0362. Epub 2014 Jan 29.

6.

Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.

Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, Brozzi F, Ceccarelli C, Viola D, Piaggi P, Vitti P, Pacini F, Elisei R.

J Clin Endocrinol Metab. 2013 Jul;98(7):2693-700. doi: 10.1210/jc.2012-4137. Epub 2013 Apr 26.

PMID:
23626005
7.

Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.

Tresoldi AS, Sburlati LF, Rodari M, Schinkelshoek M, Perrino M, De Leo S, Montefusco L, Colombo P, Arosio M, Lania AG, Fugazzola L, Chiti A.

J Endocrinol Invest. 2014 Aug;37(8):709-14. doi: 10.1007/s40618-014-0088-3. Epub 2014 May 21.

PMID:
24844565
8.

Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.

Aldawish M, Jha N, McEwan AJ, Severin D, Ghosh S, Morrish DW.

Endocr Res. 2014;39(4):157-63. doi: 10.3109/07435800.2013.865211. Epub 2014 Jan 24.

PMID:
24460082
9.

Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.

Yamazaki CA, Padovani RP, Biscolla RP, Ikejiri ES, Marchetti RR, Castiglioni ML, Matsumura LK, Maciel RM, Furlanetto RP.

Thyroid. 2012 Oct;22(10):1002-6. doi: 10.1089/thy.2011.0372. Epub 2012 Sep 6.

PMID:
22953991
10.

Clinical outcome in differentiated thyroid carcinoma and microcarcinoma.

Lupoli R, Cacciapuoti M, Tortora A, Barba L, Verde N, Romano F, Vastarella M, Fonderico F, Masone S, Milone M, Lupoli G, Lupoli GA.

Int J Surg. 2014;12 Suppl 1:S148-51. doi: 10.1016/j.ijsu.2014.05.024. Epub 2014 May 22.

11.

Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.

Patel SS, Goldfarb M.

J Surg Oncol. 2013 May;107(6):665-72. doi: 10.1002/jso.23295. Epub 2012 Nov 28. Review.

PMID:
23192391
12.

Pediatric Thyroid Cancer: Postoperative Classifications and Response to Initial Therapy as Prognostic Factors.

Lazar L, Lebenthal Y, Segal K, Steinmetz A, Strenov Y, Cohen M, Yaniv I, Yackobovitch-Gavan M, Phillip M.

J Clin Endocrinol Metab. 2016 May;101(5):1970-9. doi: 10.1210/jc.2015-3960. Epub 2016 Mar 1.

PMID:
26930182
13.

Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation.

Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, Lee DS, Lee MC, Cho BY.

Clin Endocrinol (Oxf). 2002 Aug;57(2):215-21.

PMID:
12153600
14.

Dynamic Risk Stratification in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine.

Momesso DP, Vaisman F, Yang SP, Bulzico DA, Corbo R, Vaisman M, Tuttle RM.

J Clin Endocrinol Metab. 2016 Jul;101(7):2692-700. doi: 10.1210/jc.2015-4290. Epub 2016 Mar 29.

PMID:
27023446
15.

Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.

Park S, Kim WG, Song E, Oh HS, Kim M, Kwon H, Jeon MJ, Kim TY, Shong YK, Kim WB.

Thyroid. 2017 Apr;27(4):524-530. doi: 10.1089/thy.2016.0477. Epub 2016 Dec 23.

PMID:
27869547
16.

Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation.

Hong CM, Lee WK, Jeong SY, Lee SW, Ahn BC, Lee J.

Nucl Med Commun. 2014 Nov;35(11):1119-26. doi: 10.1097/MNM.0000000000000183.

PMID:
25144561
17.

Initial and Dynamic Risk Stratification of Pediatric Patients With Differentiated Thyroid Cancer.

Sung TY, Jeon MJ, Lee YH, Lee YM, Kwon H, Yoon JH, Chung KW, Kim WG, Song DE, Hong SJ.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):793-800. doi: 10.1210/jc.2016-2666.

PMID:
27809646
18.

Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.

Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM.

Thyroid. 2013 Nov;23(11):1401-7. doi: 10.1089/thy.2013.0011. Epub 2013 Jul 25.

PMID:
23517313
19.
20.

Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.

Kammori M, Fukumori T, Sugishita Y, Hoshi M, Shimizu K, Yamada T.

Endocr J. 2015;62(12):1067-75. doi: 10.1507/endocrj.EJ15-0451. Epub 2015 Oct 1.

Supplemental Content

Support Center